Stem cells are a special type of cell that have the ability to develop and become specialized cells throughout the nervous, circulatory, and immune system. Unlike other cells, they can be isolated from adult tissue and from embryos. Stem cells have the remarkable potential to develop into different types of cells, help regenerate tissue and organs, and even kill cancer cells. The two main types of stem cells in the human body are embryonic and adult stem cells. Embryonic stem cells come from embryos, while adult stem cells are found in adult tissues such as blood, skin, heart, and other organs. Each type of stem cell has its own unique properties and can be used to research and treat different types of diseases and medical conditions. The medical applications of stem cells are vast and have potential to revolutionize the field of medicine. Stem cell scientists are researching the ability of stem cells to repair damaged and diseased tissue, reduce inflammation, treat neurological disorders, and even grow organs for transplantation. There is also potential to develop therapeutics to treat conditions such as Parkinson’s and Alzheimer’s diseases. Research is ongoing for further applications of stem cells in regenerative medicine and disease-modifying treatments. For this reason, stem cells remain one of the most promising fields of medical research. While the potential of stem cells to help treat diseases is still in its infancy, medical researchers are working tirelessly to unlock the mysteries of this exciting area of science.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States